Both PFS and OS were significantly longer in the patients with a low-CD44 expression type of GBM than those with a high-CD44 expression type of GBM (median (m) PFS: Low P/C ratio vs. High P/C ratio, 9.5 months vs. 7.0 months, p = 0.02; mOS: Low P/C ratio vs. High P/C ratio, 25.0 months vs. 14.0 months, p = 0.0000025) (Figure 4). The gene discussed is CD44; the disease is glioblastoma.